In Silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5664-5674

  Singh, Ragini ^a   Ramachandran, Vasanthi ^a,b   Shandil, Radha ^a,b   Sharma, Sreevalli ^a,b   Khandelwal, Swati ^a   Karmarkar, Malancha ^a   Kumar, Naveen ^b   Solapure, Suresh ^a,b   Saralaya, Ramanatha ^b   Nanduri, Robert ^b   Panduga, Vijender ^b   Reddy, Jitendar ^b   Prabhakar, K R ^b   Rajagopalan, Swaminathan ^a   Rao, Narasimha ^a   Narayanan, Shridhar ^a,b   Anandkumar, Anand ^a   Balasubramanian, V ^a   Dattaa, Santanu ^a  

^a ICAR National Institute of Animal Nutrition and Physiology   (India)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; BTZ 043; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; KANENDOMYCIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PRETOMANID; PROTEOME; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; STREPTOMYCIN SULFATE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENTIATION; ELIMINATION HALF-LIFE; INHIBITORY CONCENTRATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTITUBERCULAR AGENTS; ETHAMBUTOL; ISONIAZID; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; TUBERCULOSIS;

EID: 84940948147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05148-14     Document Type: Article

References (65)

1. World Health Organization. 2013. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland.
2. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388-404. http://dx.doi.org/10.1038/nrd4001.
3. Sloan DJ, Davies GR, Khoo SH. 2013. Recent advances in tuberculosis: new drugs and treatment regimen. Curr Respir Med Rev 9:200-210. http://dx.doi.org/10.2174/1573398X113099990017.
4. Davies PD. 2003. The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2:203-209. http://dx.doi.org/10.1007/BF03256649.
5. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL, Efficacy Subgroup RESIST-TB. 2013. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 207:1352-1358. http://dx .doi.org/10.1093/infdis/jis460.
6. Babu GR, Laxminarayan R. 2012. The unsurprising story of MDR-TB resistance in India. Tuberculosis (Edinb) 92:301-306. http://dx.doi.org/10.1016/j.tube.2012.02.009.
7. Barter DM, Agboola SO, Murray MB, Bärnighausen T. 2012. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa- a systematic review. BMC Public Health 12:980. http://dx.doi.org/10.1186/1471-2458-12-980.
8. Keshavjee S, Farmer PE. 2012. Tuberculosis, drug resistance, and the history of modern medicine.NEngl J Med 367:931-936. http://dx.doi.org/10.1056/NEJMra1205429.
9. Brigden G, Nyang'wa B-T, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Jr, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. 2014. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 92:68-74. http://dx.doi.org/10.2471/BLT.13.122028.
10. Barve A, Gupta A, Solapure SM, Kumar A, Ramachandran V, Seshadri K, Vali S, Datta S. 2010. A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. Adv Appl Bioinform Chem 3:97-110. http://dx.doi.org/10.2147/AABC.S14368.
11. Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Jr, Sacchettini JC. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102. http://dx.doi.org/10.1126/science.279.5347.98.
12. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 13:408-413. http://dx.doi.org/10.1038/nsmb1089.
13. Argyrou A, Vetting MW, Blanchard JS. 2007. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP. J Am Chem Soc 129:9582-9583. http://dx.doi.org/10.1021/ja073160k.
14. Wang XD, Gu J, Wang T, Bi LJ, Zhang ZP, Cui ZQ, Wei HP, Deng JY, Zhang XE. 2011. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation. Mol Microbiol 82:1375-1391. http://dx.doi.org/10.1111/j.1365-2958.2011.07892.x.
15. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. http://dx.doi.org/10.1016/S0092-8674(01)00286-0.
16. Lety MA, Nair S, Berche P, Escuyer V. 1997. A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 41:2629-2633.
17. Goude R, Amin AG, Chatterjee D, Parish T. 2009. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 53:4138-4146. http://dx.doi.org/10.1128/AAC.00162-09.
18. Jankute M, Grover S, Rana AK, Besra GS. 2012. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol 7:129-147. http://dx.doi.org/10.2217/fmb.11.123.
19. Possoz C, Newmark J, Sorto N, Sherratt DJ, Tolmasky ME. 2007. Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. Antimicrob Agents Chemother 51:252-256. http://dx.doi.org/10.1128/AAC.00892-06.
20. Kenney TJ, Churchward G. 1994. Cloning and sequence analysis of the rpsL and rpsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin. J Bacteriol 176:6153-6156.
21. Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, Mizuguchi Y, Taniguchi H. 1998. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 36:1220-1225.
22. Taniguchi H, Chang B, Abe C, Nikaido Y, Mizuguchi Y, Yoshida SI. 1997. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 179: 4795-4801.
23. Stanley RE, Blaha G, Grodzicki RL, Strickler MD, Steitz TA. 2010. The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol 17:289-293. http://dx.doi .org/10.1038/nsmb.1755.
24. Kannan K, Mankin AS. 2011. Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. AnnNY Acad Sci 1241:33-47. http://dx.doi.org/10.1111/j.1749-6632.2011.06315.x.
25. Meier A, Heifets L, Wallace RJ, Jr, Zhang Y, Brown BA, Sander P, Böttger EC. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 174:354-360. http://dx.doi.org/10.1093/infdis/174.2.354.
26. Kampranis SC, Maxwell A. 1998. Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 273:22606-22614. http://dx.doi.org/10.1074/jbc.273.35.22606.
27. Mdluli K, Ma Z. 2007. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 7:159-168. http://dx .doi.org/10.2174/187152607781001763.
28. Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. 2008. The peptidoglycan of stationary- phase Mycobacterium tuberculosis predominantly contains crosslinks generated by L, D-transpeptidation. J Bacteriol 190:4360-4366. http://dx.doi.org/10.1128/JB.00239-08.
29. Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, Boshoff HI, Barry CE, 3rd. 2012. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol 86:367-381. http://dx.doi .org/10.1111/j.1365-2958.2012.08199.x.
30. Awasthy D, Bharath S, Subbulakshmi V, Sharma U. 2012. Alanine racemase mutants of Mycobacterium tuberculosis require d-alanine for growth and are defective for survival in macrophages and mice. Microbiology 158:319-327. http://dx.doi.org/10.1099/mic.0.054064-0.
31. Prosser GA, de Carvalho LP. 2013. Metabolomics reveal D-alanine:Dalanine ligase as the target of D-cycloserine in Mycobacterium tuberculosis. ACS Med Chem Lett 4:1233-1237. http://dx.doi.org/10.1021/ml400349n.
32. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazamine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286:10276-10287. http://dx.doi.org/10.1074/jbc.M110.200501.
33. Alahari AI, Trivelli X, Guérardel Y, Dover LG, Besra GS, Sacchettini JC, Reynolds RC, Coxon GD, Kremer L. 2007. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One 2:e1343. http://dx.doi.org/10.1371/journal.pone .0001343.
34. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3:323-324. http://dx.doi.org/10.1038/nchembio884.
35. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. 2011. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One 6:e23575. http://dx.doi.org/10.1371/journal.pone.0023575.
36. Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA, Duffy EM. 2008. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 51:3353-3356. http://dx.doi.org/10.1021/jm800379d.
37. Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA824: novel insights from transcriptional profiling.CommunIntegr Biol 2:215-218. http://dx.doi.org/10.4161/cib.2.3.7926.
38. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, III, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalosemonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797-1809. http://dx.doi .org/10.1128/AAC.05708-11.
39. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K. 2010. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-D-ribose 2=-epimerase DprE1 of Mycobacterium tuberculosis. JAmChem Soc 132:13663-13665. http://dx .doi.org/10.1021/ja106357w.
40. Neidhardt FC, Ingraham JL, Low KB, Magasanik B, Schaechter M, Umbarger HE (ed). 1987. Escherichia coli and Salmonella typhimurium: cellular and molecular biology, 1st ed. American Society for Microbiology, Washington, DC.
41. Ingraham JL, Maaloe O, Neidhardt FC. 1983. Growth of bacterial cells. Sinauer Associates Inc., Sunderland, MA.
42. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11:427-433. http://dx.doi.org/10.1093/jac/11.5.427.
43. Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(Suppl 1):5-16. http://dx.doi.org/10.1093/jac/48.suppl-1.5.
44. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with clinical M. tuberculosis isolates by using the microplate Alamar blue assay. J Clin Microbiol 36:362-366.
45. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. 2011. PA824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55:239-245. http://dx.doi.org/10.1128/AAC.00849-10.
46. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint- Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804. http://dx.doi.org/10.1126/science.1171583.
47. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http://dx.doi.org/10.1128/AAC.00414-06.
48. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
49. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. 2005. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 144:80-87. http://dx.doi.org/10.1038/sj.bjp.0705984.
50. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
51. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. http://dx.doi.org/10.1016/j.cell.2007.06.049.
52. Dwyer DJ, Camacho DM, Kohanski MA, Callura JM, Collins JJ. 2012. Antibiotic-induced bacterial cell death exhibits physiological and biochemical hallmarks of apoptosis. Mol Cell 46:561-572. http://dx.doi.org/10.1016/j.molcel.2012.04.027.
53. Ramachandran V, Singh R, Yang X, Tunduguru R, Mohapatra S, Khandelwal S, Patel S, Datta S. 2013. Genetic and chemical knockdown: a complementary strategy for evaluating an anti-infective target. Adv Appl Bioinform Chem 6:1-13. http://dx.doi.org/10.2147/AABC.S39198.
54. Global Alliance for TB Drug Development. 2012. Evaluation of early bactericidal activity in pulmonary tuberculosis with clofazimine (C)-TMC207 (J)-PA-824 (Pa)-pyrazinamide (Z) (NC-003). https://clinicaltrials.gov/ct2/show/NCT01691534?term-clofazamine-PA824&rank-1.
55. Reference deleted.
56. Tasneen R, Li S-Y, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
57. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
58. Reddy VM, Einck L, Andries K, Nacy CA. 2010. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 54:2840-2846. http://dx.doi.org/10.1128/AAC.01601-09.
59. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho SN, Barry CE, III, Flynn JL. 2014. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 6:265ra167. http://dx.doi.org/10.1126/scitranslmed.3009500.
60. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. 2015. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 45:1119-1131. http://dx.doi.org/10.1183/09031936 .00162314.
61. Muñoz-Elías EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 73:546-551. http://dx.doi.org/10.1128/IAI .73.1.546-551.2005.
62. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. 2009. A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211-214. http://dx.doi.org/10.1038/nm.1915.
63. Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, Andries K, Cook GM. 2015. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 70:2028-2037. http://dx.doi.org/10.1093/jac/dkv054.
64. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (Sutezolid), TMC207, PA824, SQ109, and pyrazinamide. PLoS One 7:e30479. http://dx.doi.org/10.1371/journal.pone.0030479.
65. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. http://dx.doi.org/10.1038/35016103.